Fax: (011) 02 9113 3997
Original Article
You have full text access to this OnlineOpen article
Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma
Article first published online: 19 AUG 2010
DOI: 10.1002/cncr.25283
Copyright © 2010 American Cancer Society
Additional Information
How to Cite
Chua, T. C., Chu, F., Butler, S. P., Quinn, R. J., Glenn, D., Liauw, W. and Morris, D. L. (2010), Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma. Cancer, 116: 4069–4077. doi: 10.1002/cncr.25283
- †
Fax: (011) 02 9113 3997
Publication History
- Issue published online: 23 AUG 2010
- Article first published online: 19 AUG 2010
- Manuscript Accepted: 14 JAN 2010
- Manuscript Revised: 31 DEC 2009
- Manuscript Received: 16 OCT 2009
REFERENCES
- 1, , . Hepatocellular carcinoma. Lancet. 2003; 362: 1907-1917.
- 2, On behalf of the EGWG. Hepatocellular carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20( suppl 4): iv41-iv45.
- 3, , . The surgical management of primary carcinoma of the liver. World J Surg. 1982; 6: 66-75.
- 4, , , , , . Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995; 221: 291-298.
- 5, , , et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006; 44: 158-166; comment 2006; 44: 8-10.
- 6, , . Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004; 127( 5 suppl 1 ): S179-S188.
- 7, , , , . Solid tumor models for the assessment of different treatment modalities: I. Radiation-induced changes in growth rate characteristics of a solid tumor model. Proc Natl Acad Sci U S A. 1975; 72: 2662-2666.
- 8, , , , , . Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2002; 54: 150-155.
- 9, . Treatment of unresectable hepatocellular carcinoma with transarterial radioembolization: iodine-131-Lipiodol. ANZ J Surg. 2008; 78: 331-332.
- 10, , , . 131-iodine Lipiodol therapy in hepatocellular carcinoma. Q J Nucl Med Mol Imaging. 2009; 53: 348-355.
- 11, , , et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
- 12, , , et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2009; 14: 95-100.
- 13, , , et al. 131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2005; 17: 905-910.
- 14, , , , , . Intra-arterial injection of iodine-131-labeled Lipiodol for treatment of hepatocellular carcinoma. Radiother Oncol. 2007; 82: 76-82.
- 15, , , , . Treatment of unresectable hepatocellular carcinoma with radiolabelled Lipiodol. ANZ J Surg. 2008; 78: 371-376; comment 2008; 78: 331-332.
- 16, , , et al. Transarterial injection of I-Lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med. 2009; 50: 871-877.
- 17, , , et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med. 1994; 35: 1782-1787.
- 18, , , et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology. 1997; 26: 1156-1161.
- 19, , , et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359: 1734-1739.
- 20
- 21, , , et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35: 1164-1171.

1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
